Safety and Efficacy of Celecoxib Versus Placebo in the Treatment of Knee Osteoarthritis in Patients Who Were Unresponsive to Naproxen and Ibuprofen

Official Title: “A Double-Blind, Placebo Controlled Study of the Efficacy and Tolerability of Once Daily Celebrex (Celecoxib) vs. Placebo in the Treatment of Subjects With Osteoarthritis of the Knee Non-Responsive to Naproxen and Ibuprofen”

To compare the efficacy and safety of celecoxib versus placebo for the treatment of knee osteoarthritis (OA) in patients who were unresponsive to prescription strength naproxen and ibuprofen or who could not tolerate prescription strength naproxen and ibuprofen

Intervention(s) in this Clinical Trial

• Drug: Celecoxib
  • 200 mg oral capsule once daily with morning meal for 6 weeks
• Other: Placebo
  • Matched oral placebo for 6 weeks

Arms, Groups and Cohorts in this Clinical Trial

• Experimental: A
• Placebo Comparator: B

Primary Measures

• Change from baseline in Patient's Assessment of Arthritis Pain, according to visual analog scale (VAS)
  • Time Frame: Week 6
    Safety Issue?: No

Secondary Measures

• Patient's Assessment of Arthritis Pain, according to VAS
  • Time Frame: Week 2
    Safety Issue?: No
• The Western Ontario and McMaster Universities Osteoarthritis Index
  • Time Frame: Week 6
    Safety Issue?: No
• Patient's and Physician's Global Assessment of Arthritis
  • Time Frame: Weeks 2 and 6
    Safety Issue?: No
• The Medical Outcomes Study Sleep Scale
  • Time Frame: Week 6
    Safety Issue?: No
• Adverse events
  • Time Frame: Weeks 0-6
    Safety Issue?: Yes
• Laboratory tests
  • Time Frame: Week 6
    Safety Issue?: Yes
• Vital signs
  • Time Frame: Week 6
    Safety Issue?: Yes
• Physical examination
  • Time Frame: Week 6
    Safety Issue?: Yes
• Serious adverse events
  • Time Frame: Up to 30 days after last dose
    Safety Issue?: Yes

Inclusion Criteria:

Inclusion criteria:

• Diagnosed, active, and symptomatic OA of the knee in a flare state with a functional capacity class of I-III at baseline visit
• Failed adequate trials of both naproxen and ibuprofen (prescription strength) within the past 5 years due to lack of efficacy, tolerability, or both; duration of prescription strength ibuprofen and naproxen must have been a minimum of 2 weeks for each drug at the respective recommended doses if failure was due to lack of efficacy, and for any duration if failure was due to lack of tolerability

Exclusion Criteria:

Exclusion criteria:

• Inflammatory arthritis or gout/pseudo-gout with acute flare within the past 2 years (subjects with fibrositis or fibromyalgia will not be excluded)
• Received acetaminophen within 24 hours of the baseline visit
• Use of a mobility assisting device for less than six weeks prior to study screening or use of a walker
• History of gastrointestinal (GI) perforation, obstruction, or bleeding
• Diagnosed or treated for GI ulcer within 60 days prior to first dose of study medication
• Received corticosteroids or hyaluronic acid within certain timeframe before study

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 40 Years

Maximum Age for this Clinical Trial: N/A

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Lead Investigator: Pfizer Industry

Overall Clinical Trial Officials and Contacts

Pfizer CT.gov Call Center Study Director Pfizer  

Information obtained from ClinicalTrials.gov on February 12, 2012

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00638807

Study ID Number: A3191082

ClinicalTrials.gov Identifier: NCT00638807

Health Authority: United States: Food and Drug Administration

To obtain contact information for a study center near you, click here.